PharmiWeb.com - Global Pharma News & Resources
02-Apr-2019

Praluent® (alirocumab) now approved in European Union to reduce the risk of cardiovascular events in patients with established cardiovascular disease

 

Editor Details

Last Updated: 09-Apr-2019